Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rectal Cancer: Determination of the Predictive Value by Use of FDG-PET-CT Scans and Blood Proteins for the Prognosis of Patients With Rectal Cancer

NCT00576563 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT00576563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00576563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rectal Cancer: Determination of the Predictive Value by Use of FDG-PET-CT Scans and Blood Proteins for the Prognosis of Patients With Rectal Cancer
Lead sponsor
Maastricht Radiation Oncology
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2007
Completion date
December 31, 2015
Enrollment
103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectum cancer